PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Medigene AG Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.	Germany	MDG1
MedinCell S.A. Develops long-acting injectable therapies using proprietary technology to impact global health.	France	MEDCL
MEDINET Co., Ltd. A CDMO for cell therapy and regenerative medicine development & manufacturing.	Japan	2370
Medios AG Compounding patient-specific therapies and supplying specialty pharma for complex conditions.	Germany	ILM1
MEDIPOSTCO.,LTD. Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.	South Korea	078160
MediWound Ltd. Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.	United States of America	MDWD
Medizen Humancare Inc Co., Ltd Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.	South Korea	236340
Medy-Tox Inc. Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.	South Korea	086900
MeiraGTx Holdings plc Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.	United States of America	MGTX
Meito Sangyo Co., Ltd. Produces food products and specialty chemicals for industrial and pharmaceutical applications.	Japan	2207